199678-12-1

Basic information

• Product Name: 4-(Pyrimidin-2-yl)benzoic acid
• Synonyms: AKOS BAR-2339;4-(PYRIMIDIN-2-YL)BENZOIC ACID;Benzoic acid, 4-(2-pyrimidinyl)- (9CI);4-Pyrimidin-2-yl-benzoicacid95%
• CAS NO: 199678-12-1
• Molecular Formula: C₁₁H₈N₂O₂
• Molecular Weight: 200.19
• Product Categories: QUINAZOLINE;pharmacetical
• Mol File: 199678-12-1.mol

Chemical Properties

• Melting Point: 238 °C
• Boiling Point: 301.5 °C at 760 mmHg
• Flash Point: 136.2 °C
• Appearance: /
• Density: 1.302 g/cm³
• Vapor Pressure: 0.000464mmHg at 25°C
• Refractive Index: 1.619
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 3.67±0.10(Predicted)
• CAS DataBase Reference: 4-(Pyrimidin-2-yl)benzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(Pyrimidin-2-yl)benzoic acid(199678-12-1)
• EPA Substance Registry System: 4-(Pyrimidin-2-yl)benzoic acid(199678-12-1)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 199678-12-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-(Pyrimidin-2-yl)benzoic acid is used as a reactant for the synthesis of alkylimino-quinolinyl isoindolones, which are compounds with potential applications in the development of new drugs. These synthesized molecules may exhibit various biological activities, such as anti-cancer, anti-inflammatory, or anti-microbial properties, making them valuable in the creation of novel therapeutic agents.
Used in Chemical Industry:
In the chemical industry, 4-(Pyrimidin-2-yl)benzoic acid serves as an important building block for the synthesis of a wide range of organic compounds. Its unique structure allows for further functionalization and modification, leading to the development of new materials with specific properties and applications, such as dyes, pigments, or advanced materials for various industrial uses.

InChI:InChI=1/C11H8N2O2/c14-11(15)9-4-2-8(3-5-9)10-12-6-1-7-13-10/h1-7H,(H,14,15)

Upstream product

• 466634-79-7 4-pyrimidin-2-ylbenzoic acid methyl ester 
• 99768-12-4 4-methoxycarbonylphenylboronic acid 
• 87199-17-5 4-formylphenylboronic acid, 
• 77232-38-3 4-(2-pyrimidinyl)-benzaldehyde 
• 14047-29-1 4-carboxyphenylboronic acid 
• 4595-60-2 2-bromopyrimidine 

Downstream Products

• 68049-17-2 2-(4-fluorophenyl)-pyrimidine 
• 259541-90-7 1-(4-(pyrimidin-2-yl)phenyl)ethan-1-one 
• 1441810-31-6 C₄₁H₄₀N₄O₅ 
• 679806-84-9 4-pyrimidin-2-yl-benzoyl chloride 

Relevant articles and documents

LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism

Oxytocin (OT) and its receptor (OT-R) are implicated in the etiology of autism spectrum disorders (ASD), and OT-R is a potential target for therapeutic intervention. Very few nonpeptide oxytocin agonists have currently been reported. Their molecular and in vivo pharmacology remain to be clarified, and none of them has been shown to be efficient in improving social interaction in animal models relevant to ASD. In an attempt to rationalize the design of centrally active nonpeptide full agonists, we studied in a systematic way the structural determinants of the affinity and efficacy of representative ligands of the V1a and V2 vasopressin receptor subtypes (V1a-R and V2-R) and of the oxytocin receptor. Our results confirm the subtlety of the structure-affinity and structure-efficacy relationships around vasopressin/oxytocin receptor ligands and lead however to the first nonpeptide OT receptor agonist active in a mouse model of ASD after peripheral ip administration.

KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE

Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation of cancer cells in a human or animal subject are also provided for the treatment of diseases such as acute myelogenous leukemia.

ANTI-HCMV COMPOSITIONS AND METHODS

Novel compounds useful for treating and/or preventing HCMV infections are provided.

Benzoimidazole derivatives and pharmaceutical composition comprising the same

Disclosed herein are novel benzoimidazole derivatives functioning as antagonists to vanilloid receptor-1, and a pharmaceutical composition comprising the same. They are useful in preventing or treating pain, acute pain, chronic pain, neuropathic pain, pos

PYRROLIDINE OR THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERSAS AS AGONISTS OF G- PROTEIN COUPLED RECEPTOR 43 (GPR43)

The present invention is directed to novel compounds of formula (I) and their use in treating and/or preventing metabolic diseases.

Pyrrolobenzodiazepine pyridine carboxamides and derivatives as follicle-stimulating hormone receptor antagonists

This invention provides pyrrolobenzodiazepine pyridine carboxamides selected from those of Formula (1), which act as follicle stimulating hormone receptor antagonists. The invention also provides pharmaceutical compositions and methods of treatment utilizing the compounds of Formulae (1) and (2).

Biarylcarboxybenzamide derivatives as potent vanilloid receptor (VR1) antagonistic ligands

Seventeen biarylcarboxybenzamide derivatives were prepared for the study of their agonistic/antagonistic activities to the vanilloid receptor (VR1) in rat DRG neurons. The replacement of the piperazine moiety of the lead compound 1 with phenyl ring showed quite enhanced antagonistic activity. Among the prepared derivatives, N-(4-tert-butylphenyl)-4-pyridine-2-yl-benzamide (2, IC 50 = 31 nM) and N-(4-tert-butylphenyl)-4-(3-methylpyridine-2-yl) benzamide (3g, IC50 = 31 nM), showed 5-fold higher antagonistic activity than 1 in 45Ca2+-influx assay.

A convenient synthesis of heteroaryl benzoic acids via Suzuki reaction

An one step approach to heteroaryl benzoic acids from readily accessible heteroaryl halides and carboxybenzene boronic acids is described. The Suzuki coupling is carried out in the presence of Pd(PPh3)4 and sodium carbonate in aqueous acetonitrile. The scope and limitations of the reaction are discussed.